JGC
PRVB

J. Goldman & Co’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

J. Goldman & Co’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,211
Closed -$495K – 557
2020
Q4 		$495K Sell
29,211
-13,580
-32% -$204K 0.03% 279
2020
Q3 		$549K Sell
42,791
-21,803
-34% -$275K 0.04% 246
2020
Q2 		$911K Buy
64,594
+44,595
+223% +$563K 0.06% 198
2020
Q1 		$184K Sell
19,999
-23,661
-54% -$305K 0.02% 214
2019
Q4 		$651K Buy
+43,660
New +$389K 0.05% 206

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

J. Goldman & Co's PRVB Position: Q1 2021 in Review

J. Goldman & Co sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2021, closing a stake of 29,211 shares — an estimated $495K sold.

J. Goldman & Co first reported a position in PRVB in Q4 2019 and held it in 5 quarters. The position peaked at $911K in Q2 2020. 120 funds tracked by Wall St. Rank hold PRVB as of Q1 2021.

  • J. Goldman & Co reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 29,211 Provention Bio, Inc. Common Stock shares in Q1 2021, an estimated $495K.
  • J. Goldman & Co first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • J. Goldman & Co's Provention Bio, Inc. Common Stock position peaked at $911K in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.